Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

Publisher： Bentham Science Publishers

E-ISSN： 1875-6913|7|1|1-26

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.7, Iss.1, 2009-03, pp. : 1-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction: Are All HMG-CoA Reductase Inhibitors Alike?

By Maroo Bijesh P.   Lavie Carl J.   Milani Richard V.  

Drugs & Aging, Vol. 25, Iss. 8, 2008-01 ,pp. : 649-664

Adis International

Access to resources Recommend Favorite

HMG-CoA Reductase Inhibitors in the Prevention of Stroke

By van Mil A.H.M.  

Drugs, Vol. 59, Iss. 1, 2000-01 ,pp. : 1-6

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease: The Problem of Under-Treatment

By McCabe C.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 3, 2003-01 ,pp. : 179-191

Adis International

Access to resources Recommend Favorite

The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function

By Tesfamariam Belay  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 2, 2006-01 ,pp. : 115-120

Adis International

Access to resources Recommend Favorite

Comparative Tolerability of the HMG-CoA Reductase Inhibitors

By Farmer J.A.   Torre-Amione G.  

Drug Safety, Vol. 23, Iss. 3, 2000-09 ,pp. : 197-213

Adis International

Access to resources Recommend Favorite